Skip to main content

Table 2 Relative Treatment Effects for LMWH/VKA and Placebo versus Apixaban§

From: Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences

 

Initial LMWH/VKAa

95% Confidence Interval

Extended Placebob

95% Confidence Interval

Extended VKAsc

95% Confidence Interval

Relative risks

Recurrent VTE and VTE-related death

1.18

0.83–1.66

5.33

3.02–9.40

0.42

0.16–1.06

Major bleed

3.26

1.84–5.79

2.07*

0.38–11.24

7.7

1.09–76.40

CRNM bleed

2.09

1.66–2.63

0.78

0.43–1.40

3.84

1.55–9.38

Other treatment discontinuation

1.07§

0.85–1.35§

-

 

1.33

0.75–1.87

  1. *Absolute event rates for major bleed, apixaban: 0.0024, placebo: 0.0048
  2. §The resulting risks for placebo and LMWH/VKA are detailed in the Additional file 2
  3. Source:
  4. aAMPLIFY [12]
  5. bAMPLIFY-EXT [13]
  6. cNMA (presented in the Additional file 2)
  7. §Data on file: Secondary Analysis of AMPLIFY (CV185-056) to Support Apixaban Cost Effectiveness Modeling for the Indication of Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Venous Thromboembolisim (OR APIX 025). 2014